罗氏格菲妥单抗新适应症在华获批

Core Viewpoint - Roche Pharmaceuticals China has received approval from the National Medical Products Administration of China for its innovative bispecific antibody Glofitamab (Columvi) for a new indication, which is to be used in combination with Gemcitabine and Oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are unsuitable for autologous stem cell transplantation (ASCT) [1] Group 1 - The new indication for Glofitamab targets a specific patient population with DLBCL NOS [1] - The approval highlights Roche's commitment to expanding treatment options for patients with challenging cancer types [1] - The combination therapy aims to improve outcomes for patients who have limited treatment options [1]